JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:18-22, doi:10.1016/j.jacc.2006.04.041
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wagoner, L. E.
Right arrow Articles by O’Connor, C. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wagoner, L. E.
Right arrow Articles by O’Connor, C. M.

Cardiac Function and Heart Failure

Lynne E. Wagoner, MD, FACC*,*, Randall C. Starling, MD, MPH, FACC{dagger} and Christopher M. O’Connor, MD, FACC{ddagger}

* Heart Failure and Cardiac Transplant Program, University of Cincinnati, Cincinnati, Ohio
{dagger} Cleveland Clinic, Cleveland, Ohio
{ddagger} Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina.


Figure 1
View larger version (14K):

[in a new window]
  		Figure 1 Heart failure composite outcome (death, hospitalization, or discontinuation for worsening heart failure, heart failure classification, and/or global assessment score at eight months) (primary end point), Pediatric Carvedilol Study Group. p = 0.74 carvedilol combined versus placebo. Blue bars = improved; yellow bars = unchanged; green bars = worsened.

 

Figure 2
View larger version (14K):

[in a new window]
  		Figure 2 Survival after heart failure hospital discharge. Reprinted with permission (4).

 

Figure 3
View larger version (20K):

[in a new window]
  		Figure 3 Use percentage of patients showing a ≥6 mEq/l increase in serum sodium or normal serum sodium at the end of intravenous conivaptan (CNV) treatment. *p = 0.0359; {dagger}p = 0.0025; {ddagger}p = 0.032; §p = 0.0023 vs. placebo from Cochran-Mantel-Haenszel test. Adapted with permission (8). HF = heart failure.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.